Monday, January 13, 2014

Brain Cancer Research & Understanding A Particular Hybrid

By Robert Sutter

Glioblastoma is one of those conditions in which brain cancer research is going to play into tremendously. There is so much that can be said about this and I do not think that anyone in this particular field can say differently. However, what if I were to tell you that a potential drub combination could come into play for the sake of bringing positive news to this level of research? This is something that is worth noting, especially when you take into consideration just serious this particular ailment is.

US News and World Report posted an article about a potential treatment that could prove useful for the sake of treating glioblastoma. This is one point that should be looked into but you have to keep in mind that this condition stands as one of the most aggressive and common conditions seen in the brain. According to a study that was done by the University of Zurich, it is "virtually incurable." That being said, it seems like a two-pronged drug therapy approach could prove useful in the long term.

The study group at the university looked into this condition more so, utilizing mice in order to see how a drug combination could be utilized. The mice were given both a T cell-boosting protein - dubbed interleukin-12 - as well as a drug that would be able to block off the inhibitory function that is commonly associated with the T cell. Keep in mind that while only IL-12 could be put to use, it was determined that mice had a boosted survival rate of 25%. However, the results should not stop at this point, should they?

To me, this is one of the best cases that can be taken into account and I do not think that anyone in the realm of brain cancer research can overlook this. This is especially true when you take into consideration that the T cells, thanks to the incorporation of another drug, can be halted in terms of regulation. The way that this could prove beneficial is through the survival rate boosting from 25% to 80%. It's a great point to consider, which is especially true for organizations along the lines of V-A-B-C.

No matter where the results of the study go, I do not think that anyone can argue with the fact that possibilities are going to be focused on in great detail. Brain cancer research is all about finding out what is going to work best in the long term, which is something that should go without saying. Sometimes, though, researchers have to be able to find more unique combinations that have potential healing properties. This story, in my opinion, is one that can bring even greater results about in due time.

About the Author:

No comments:

Post a Comment